Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Who Have Failed Standard Available Therapy

Trial Profile

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Who Have Failed Standard Available Therapy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HPN 536
  • Indications Carcinoma; Mesothelioma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Harpoon Therapeutics
  • Most Recent Events

    • 06 Nov 2019 According to a Harpoon Therapeutics media release, the company plans to present present proof of concept data for HPN536 in 2020.
    • 05 Aug 2019 According to a Harpoon Therapeutics media release, first patient was dosed,and two dosing cohorts have been completed.
    • 09 Apr 2019 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top